A case of interstitial pneumonitis associated with Guillain-Barré syndrome during administration of adjuvant trastuzumab.
Autor(es): Bettini Anna Cecilia,Tondini Carlo,Poletti Paola,Caremoli Elena Rota,Guerra Ugo,Labianca Roberto
Resumo: Optimal treatment for HER2/neu-positive, node-positive early breast cancer should include the monoclonal antibody trastuzumab. This relatively new agent has shown very limited pulmonary toxicity. Our report describes a case of life-threatening interstitial pneumonitis associated with Guillain-Barré syndrome that occurred during the administration of adjuvant trastuzumab. The severity of the clinical presentation and the limited number of reports in the literature of acute trastuzumab-related lung injury make the description of this case of crucial interest.
Imprenta: Tumori, v. 94, n. 5, p. 737-741, 2008
Descritores: Guillain-Barre Syndrome - Cytopathology ; Guillain-Barre Syndrome - Pathogenesis ; Guillain-Barre Syndrome - Proteins ; Guillain-Barre Syndrome - Antibodies ; Guillain-Barre Syndrome - Public health
Data de publicação: 2008
